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Overall, clinicians’ preferences for drugs delivered via intrathecal pumps were 
driven by patient-related health factors.
PND57
Barriers To PrescriBiNg MeDicaTioNs To PaTieNTs WiTh MulTiPle 
sclerosis: a coMParisoN of healTh care ProviDer PercePTioNs iN 
euroPeaN uNioN (eu) aND The uNiTeD sTaTes
Narayanan S.1, Khan H.2, Gabriele S.2, White J.2
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess health care provider (HCP) perception of barriers to pre-
scribing medications to patients with Multiple Sclerosis (MS) in EU and the 
US. MethOds: A multi-country HCP survey was conducted in 5EU (UK/Germany/
France/Spain/Italy) and the US as part of a retrospective chart-review study of MS 
patients. HCPs (mostly physicians) were screened for experience (> = 3yrs) and 
patient volume (> 15MS patients/month) and recruited from a large HCP-panel to 
be geographically representative in each country. Practice characteristics, HCP per-
ceptions and practice patterns were assessed. HCP perceptions of the following 
barriers to prescribing interferons (all types), glatiramer acetate, natalizumab and 
fingolimod were assessed: patients prefer other medications (barrier-1), availability/
cost (barrier-2), guidelines/license restrictions (barrier-3) and drug-related issues 
(barrier-4). Summary statistics are reported. ResULts: In 4Q2012, 360 HCPs (nerol-
ogists:95%; nurses:5% (from UK only)) participated. Mean age (5EU/US):45/50yrs; 
female (5EU/US):34%/21%; years practicing in neurology (5EU/US):16/19yrs; practice-
location (> = 50% of time in hospital-setting; 5EU/US):83%/26%; % HCPs seeing MS 
patients in specialty clinic (5EU/US):53%/27%; % HCPs with MS as the main focus 
area (5EU/US):68%/40%. Geographic distribution of HCPs was: 5EU-72% (UK-16%, 
Germany/France/Spain/Italy-14% each), US-28%. Patient volume/month per HCP 
was (5EU/US): All-patients-254/319, MS-patients-61/68. MS patient-type seen was 
(5EU/US): relapsing-remitting-52%/58%, relapsing secondary progressive-13%/13%, 
non-relapsing secondary progressive-13%/12%, primary progressive-8%/6%, clini-
cally isolated syndrome-9%/7%, benign-6%/4%. Average prescriptions written/month 
for MS-treatments was (5EU/US):51/62. Key barriers to prescribing interferons were 
(5EU/US): barrier-1:12%/13%, barrier-2:11%/21%, barrier-3:9%/8%, barrier-4:55%/56%, 
no-barrier:30%/24%; for glatiramer (5EU/US): barrier-1:14%/12%, barrier-2:9%/18%, 
barrier-3:8%/6%, barrier-4:62%/60%, no-barrier:28%/28%; for natalizumab (5EU/
US): barrier-1:16%/17%, barrier-2:28%/36%, barrier-3:47%/23%, barrier-4:81%/92%, 
no-barrier:15%/5%; for fingolimod (5EU/US): barrier-1:5%/21%, barrier-2:35%/48%, 
barrier-3:49%/21%, barrier-4:65%/84%, no-barrier:17%/4%. cOncLUsiOns: Drug-
related issue was the most frequently cited barrier to prescribing MS medications 
both in 5EU and the US. Drug availability/cost and guidelines/license restrictions 
were more often cited by HCPs in the US and 5EU respectively. Impact of these bar-
riers on optimal patient management and outcomes may warrant further research.
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Objectives: The purpose of this study was to understand how United States payers 
manage novel oral, high cost MS medications in consideration of the availability of 
lower cost injectable treatments, generally considered less convenient regarding 
administration while in line with the efficacy of orals. MethOds: The respective 
tier statuses and utilisation management of teriflunomide, fingolimod, dimethyl 
fumarate, interferon beta-1a (AVONEX and REBIF), and glatiramer acetate at 46 plans 
were audited: 18 Medicare, 12 national private (including PBMs), and 16 regional 
and state private plans. Access to oral MS treatments was compared to that of 
injectable MS treatments to identify differences in tiering or utilisation manage-
ment. ResULts: 54% of plans demonstrated preferential coverage of injectable MS 
therapies over orals, by lower tier status or lighter utilisation management. By seg-
ment, regional and state private plans demonstrated the strongest preference for 
injectables, with 75% of these plans demonstrating this preference compared to 50% 
of Medicare and 33% of national private plans. Plans employing prior authorisation 
or step edits to manage oral MS therapies usually stepped orals through injectables. 
Among oral MS products, national private and Medicare plans tended to prefer 
fingolimod, with 50% and 61% of plans preferring it over at least one other oral MS 
product, respectively. 19% of regional and state private plans preferred dimethyl 
fumarate over at least one other oral MS product. cOncLUsiOns: United States pay-
ers take varying approaches to the management of oral MS medications; however, 
virtually no plans offer preferential access to orals over injectables. The sample is 
roughly split between plans preferring injectable MS products over orals and those 
offering roughly parity access.
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Objectives: Cleft lip with and without cleft palate is the second most prevalent 
birth defect in the United States. Previous epidemiological studies of cleft lip surgery 
have been plagued by multiple design and methodological issues, including failure 
to adjust costs, grouping of cleft lip only (CL) with cleft lip and palate (CLP) diagno-
ses, and improper definition of secondary cleft lip surgery. The objective of this study 
was to provide national estimates of primary and secondary cleft lip surgery using 
cohort definitions based on national treatment guidelines. MethOds: The nation-
ally representative Kids’ Inpatient Database (KID) was used for this study. Years 
analyzed included 2003, 2006, and 2009. Subjects were identified by International 
Classification of Diseases Ninth Revision (ICD-9) diagnosis of cleft lip only or cleft 
lip and palate. Primary surgery was defined as a surgery before two years of age with 
the ICD-9 procedural code for cleft lip repair. Secondary surgery was defined as a sur-
Objectives: The Ontario Drug Policy Research Network has received provincial gov-
ernment funding to conduct research relating to formulary modernization within 
the Ontario Public Drug Programs. This innovative, integrated program for drug 
class reviews incorporates a novel methodological technique called reimbursement-
based economics which focuses on reimbursement strategies. The first class review 
related to triptans for migraines. In Ontario, triptans are currently available through 
the Exceptional Access Program (EAP). Specific research questions related to the 
current evidence for the cost-effectiveness of triptans and the economic impact 
of alternative changes to their funding status. MethOds: Systematic review of 
cost-effectiveness studies of triptans focusing on strength and quality of evidence. 
2. Applied, policy-oriented reimbursement based economic model developed to 
forecast budget expenditure for each alternative reimbursement strategy (generic 
pricing, generic substitution, quantity limits and/or more liberal access). ResULts: 
21 economic studies were identified though many had a number of common limita-
tions reducing their usefulness in aiding decision making. The weight of evidence 
suggests that triptans are more cost effective than ergots, in patients experienc-
ing acute migraine. Maintaining triptans within the EAP with generic equivalents 
costing 25% of branded products reduces expenditure by 18%-85%. Greater access 
to triptans but with a quantity limit of 6 units per month would increase total 
expenditure by between 133%-140%: less restrictive quantity limits would lead to 
expenditure increases of up to 326%. cOncLUsiOns: Evidence suggests that, for 
migraine, triptans are cost effective compared to ergots. Allowing greater access to 
triptans would significantly increase expenditure and may lead to use in a wider 
population where neither effectiveness nor cost effectiveness has been established. 
Maintaining triptan coverage through EAP with generic equivalents costing 25% of 
branded products combined with generic substitution will reduce total expendi-
tures by 67%. Other factors will be considered before final recommendations on 
formulary changes are made.
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Objectives: The first oral disease modifying therapy (DMT) was approved in the fall 
of 2010, the second followed two years later with a short six-month gap before the 
third approval. This study sought to describe and compare patients prescribed one 
of the three oral DMTs available to treat relapsing forms of multiple sclerosis (MS) 
in the US. MethOds: Adult patients with a claim for fingolimod, teriflunomide or 
dimethyl fumarate on or after September 22, 2010 (‘index’) were identified in the 
Truven Health MarketScan® databases. Patients had an MS diagnosis (ICD-9-CM 
340) in the 12 months prior to index, continuous enrollment 12 months pre- and 3 
months post-index and a confirmatory claim for their index drug. Demographic, 
clinical and severity characteristics were measured and compared in the 12 month 
baseline period. ResULts: A total of 3,379 patients were included, mean age 46.3 
(SD 10.5), 75.4% female. The majority (85.8%, n= 2,899) indexed on fingolimod, with 
10.0% (n= 339) indexing on teriflunomide and the remaining 4.2% (n= 141) indexing 
on dimethyl fumarate. Patients indexing on teriflunomide and dimethyl fumarate 
were significantly older than those indexing on fingolimod (50.0 [SD 9.6] and 48.1 
[SD 10.4] vs. 45.8 (SD 10.2), respectively, both p< 0.01). A greater proportion of patients 
indexing on teriflunomide had chronic pain, high blood pressure and high choles-
terol than those indexing on fingolimod (47.2% vs.40.8%, 30.4% vs. 19.7% and 24.5% 
vs. 15.8%, respectively, all p< 0.05) and a greater proportion of patients indexing on 
dimethyl fumarate had arthritis and thyroid disease than those indexing on fin-
golimod (13.5% vs. 6.9% and 13.5% vs. 8.1%, both p< 0.05). cOncLUsiOns: Factors 
in the decision to start disease modifying therapy with one of the oral medications 
can be complex. This study showed that older patients with more comorbid disease 
are being channeled to the two newest oral medications on the market.
PND56
cliNical PracTice of iNTraThecal Drugs for MaNageMeNT of PaiN aND 
sPasTiciTy: a MulTiNaTioNal cross-secTioNal survey of healTh care 
ProviDers
Chawla A.S.1, Horowicz-Mehler N.2, Faulkner E.C.3, Strassels S.4, Saake L.4
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Global Consulting, New York, NY, USA, 
3Quintiles Global Consulting, Durham, NC, USA, 4Mallinckrodt Pharmaceuticals, Hazelwood, MO, 
USA
Objectives: Intrathecal drug therapy via implanted pump for treatment of spas-
ticity and chronic pain is highly varied and may have significant implications for 
patient outcomes. The objectives of this study were to: 1) characterize factors 
that influence real-world usage of these drugs, and 2) identify key differences 
and similarities in clinical practice, along with unmet needs across global mar-
kets. MethOds: A cohort of 96 health care providers (HCPs) was surveyed across 6 
countries, Canada (16), France (15), Italy (10), Germany (20), UK (15), and US (20). The 
HCPs included physicians and nurses caring for patients with intrathecal pumps 
across multiple specialties. ResULts: Compounded vs Manufacturer-prepared: 
While respondents cited continued need for compounded drugs (66%), comparable 
manufacturer-prepared drugs, if available, were preferred by at least 33% (highest 
in Germany, 45%), even at a higher procurement cost (20%). Over 25% respondents 
expressed concern over compounded drugs, including limited regulation, vari-
able efficacy, and potential for sterility issues. 1) Dosage: Depending on the drug, 
from 60% to 90% of respondents expressed interest in new manufacturer-prepared 
doses; 2) Packaging Format: Over 77% respondents preferred pre-filled syringes 
over ampules (18%) or vials (5%), largely due to ease of use and sterility. Despite this 
preference, 65% of respondents were concerned about the associated higher cost of 
prefilled syringes. cOncLUsiOns: This cross-sectional survey identified consist-
ent themes across the 6 markets. Unmet needs identified included opportunities 
for manufacturer-prepared drugs, new packaging forms, and new concentrations. 
